Recent Updates
Recently added Catalysts
ARVN Positive Sentiment Score: 75/100

Arvinas to Participate in Upcoming Investor Conferences

Monday, February 27, 2023 2 min read
Key Takeaway: Arvinas, Inc. announced its participation in two upcoming investor conferences: the Cowen 43rd Annual Health Care Conference on March 6 and the Oppenheimer 33rd Annual Healthcare Conference on March 13. Management will host fireside chats during these events, providing insights into the company's drug development initiatives. Arvinas focuses on pioneering therapies that target and degrade disease-causing proteins, with several ongoing clinical programs for cancer treatments. This commitment highlights the company's engagement with investors and potential for future advancements in biotechnology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arvinas is participating in two significant investor conferences, showcasing their commitment to transparency and engagement with stakeholders.
  • The company has a robust preclinical pipeline and ongoing clinical-stage programs, indicating strong potential for future growth.
  • The innovative PROTAC® Discovery Engine platform reflects Arvinas's dedication to advancing drug development.

Full Press Release Details

NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
Cowen 43rd Annual Health Care Conference on Monday, March 6. Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13. Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Jeff.Boyle@arvinas.com
Kirsten.Owens@arvinas.com

Tags

targetedproteindegradation

Frequently Asked Questions

What is Arvinas known for?

Arvinas focuses on creating drugs through targeted protein degradation.

When is the Cowen Healthcare Conference?

The Cowen 43rd Annual Health Care Conference is on March 6, 2023.

Who will represent Arvinas at the Oppenheimer Conference?

Ron Peck, M.D., and Randy Teel, Ph.D., will represent Arvinas.

What are PROTAC® targeted protein degraders?

They are engineered drugs that selectively degrade disease-causing proteins.

What diseases does Arvinas aim to treat?

Arvinas targets serious diseases like metastatic prostate and breast cancers.

Tags: ARVN Viatris Investor Conferences Healthcare Arvinas cancer treatments biotechnology clinical-stage
Last updated: Feb 27, 2023